Cue Begin Period Cash Flow from 2010 to 2024
| CUE Stock | USD 1.05 0.01 0.96% |
Begin Period Cash Flow | First Reported 2016-09-30 | Previous Quarter 41 M | Current Value 30 M | Quarterly Volatility 23.7 M |
Check Cue Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cue Biopharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.6 M, Interest Expense of 1.2 M or Selling General Administrative of 11.7 M, as well as many indicators such as Price To Sales Ratio of 20.9, Dividend Yield of 0.0 or PTB Ratio of 3.09. Cue financial statements analysis is a perfect complement when working with Cue Biopharma Valuation or Volatility modules.
Cue | Begin Period Cash Flow |
Latest Cue Biopharma's Begin Period Cash Flow Growth Pattern
Below is the plot of the Begin Period Cash Flow of Cue Biopharma over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. Cue Biopharma's Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cue Biopharma's overall financial position and show how it may be relating to other accounts over time.
| Begin Period Cash Flow | 10 Years Trend |
|
Begin Period Cash Flow |
| Timeline |
Cue Begin Period Cash Flow Regression Statistics
| Arithmetic Mean | 28,471,001 | |
| Geometric Mean | 17,549,015 | |
| Coefficient Of Variation | 91.43 | |
| Mean Deviation | 23,396,851 | |
| Median | 14,925,820 | |
| Standard Deviation | 26,031,011 | |
| Sample Variance | 677.6T | |
| Range | 68.6M | |
| R-Value | 0.81 | |
| Mean Square Error | 249.9T | |
| R-Squared | 0.66 | |
| Significance | 0.0002 | |
| Slope | 4,720,197 | |
| Total Sum of Squares | 9486.6T |
Cue Begin Period Cash Flow History
About Cue Biopharma Financial Statements
Cue Biopharma stakeholders use historical fundamental indicators, such as Cue Biopharma's Begin Period Cash Flow, to determine how well the company is positioned to perform in the future. Although Cue Biopharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Cue Biopharma's assets and liabilities are reflected in the revenues and expenses on Cue Biopharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Cue Biopharma. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Begin Period Cash Flow | 51.8 M | 47 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cue Biopharma is a strong investment it is important to analyze Cue Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cue Biopharma's future performance. For an informed investment choice regarding Cue Stock, refer to the following important reports:Check out the analysis of Cue Biopharma Correlation against competitors. For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cue Biopharma. If investors know Cue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cue Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.91) | Revenue Per Share 0.172 | Quarterly Revenue Growth 0.923 | Return On Assets (0.52) | Return On Equity (1.39) |
The market value of Cue Biopharma is measured differently than its book value, which is the value of Cue that is recorded on the company's balance sheet. Investors also form their own opinion of Cue Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Cue Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cue Biopharma's market value can be influenced by many factors that don't directly affect Cue Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cue Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cue Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cue Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.